Duvyzat (Givinostat) for Muscular dystrophy

Overview
Duvyzat is approved by the U.S. Food and Drug Administration (FDA) for treating Duchenne muscular dystrophy (DMD) in people who are 6 years of age and older. A person must undergo evaluations of their platelet counts and triglycerides before starting treatment to ensure they are within safe ranges, as low platelet levels may prevent treatment initiation. Duvyzat is also known by its drug name, givinostat.

Duvyzat is a histone deacetylase inhibitor that may help manage DMD by modifying gene expression to reduce inflammation and muscle degradation, potentially slowing the progression of muscle weakness in affected individuals.

How do I take it?
Prescribing information states that Duvyzat should be taken as an oral suspension twice daily with food. The specific dosage is determined by the recipient’s body weight. Dose adjustments may be required in response to changes in platelet counts, gastrointestinal symptoms, elevated triglycerides, or QTc prolongation (a heart rhythm abnormality). Duvyzat should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Duvyzat include diarrhea, abdominal pain, thrombocytopenia (low platelet count), nausea/vomiting, elevated triglycerides (fats in the blood), and pyrexia (fever).

Rare but serious side effects may include hematological changes (such as severe thrombocytopenia, anemia, or neutropenia, which is low levels of white blood cells), severe gastrointestinal issues, and QTc prolongation (a condition affecting heart rhythm that can increase the risk of serious arrhythmias). Regular monitoring by a health care provider is recommended to manage these potential risks.

For more information about this treatment, visit:

Label: Duvyzat — Givinostat Suspension — DailyMed

Duvyzat — Drugs.com